Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Merida Biosciences is a new biotech company focused on developing precision treatments, particularly for autoimmune diseases. The company utilize a protein engineering platform to create unique Fc therapeutics, aiming to selectively bind to specific antibodies.
Private Equity Round in 2025
Caris Life Sciences is a biosciences company that focuses on improving cancer patient outcomes through advanced molecular profiling and diagnostic technologies. It specializes in various areas of pathology, including oncology, dermatopathology, hematopathology, gastrointestinal pathology, and urologic pathology. The company offers a range of services, including prognostic testing, genomic profiling, transcriptomic and proteomic analyses, and the Comprehensive Oncology Data Explorer, a clinico-genomic data platform. By utilizing artificial intelligence and machine learning, Caris Life Sciences analyzes complex molecular data to aid healthcare providers in making informed treatment decisions. The company, founded in 1987 and headquartered in Irving, Texas, serves a global clientele through distributors in the United States, Europe, and Australia, and has additional offices in Phoenix and Basel. Caris Life Sciences also collaborates with various partners to enhance its offerings and expand its impact in the field of personalized medicine.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.
Ocuphire Pharma is a clinical-stage biopharmaceutical company based in Farmington Hills, Michigan, that specializes in developing and commercializing therapies for various ophthalmic disorders. The company’s lead product candidate is Nyxol, a once-daily preservative-free eye drop formulation designed to treat conditions such as dim light vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Nyxol is currently in late-stage clinical development, supported by extensive safety and efficacy data from previous trials. Additionally, Ocuphire is advancing APX3330, an oral tablet aimed at addressing diabetic retinopathy and diabetic macular edema, which is in Phase 2 clinical development. The company is also exploring opportunities to acquire further ophthalmic assets and seeks strategic partnerships for global commercialization of its products.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.
Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.
RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.
Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.
Zucara Therapeutics Inc. is a biotechnology company based in Toronto, Canada, with an additional office in Vancouver. Founded in 2014, the company focuses on developing innovative therapeutics aimed at preventing hypoglycemia, or low blood sugar, in patients with diabetes. Its lead pre-clinical technology targets somatostatin type 2 receptors in the pancreas, which are inadequately regulated in individuals with Type 1 diabetes. By blocking these receptors, Zucara's treatment aims to prevent hypoglycemia and restore natural glucose levels in the bloodstream. This approach represents a significant advancement over existing therapies, which typically only address hypoglycemia after it has occurred, rather than preventing it from happening in the first place.
Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting KCC2, a key mediator of inhibition in the brain. The company utilizes a proprietary discovery engine centered on the neuron-specific K-Cl cotransporter (KCC2) to address various conditions, including epilepsy and pain, as well as other central nervous system pathologies. By harnessing breakthrough research from institutions such as Boston Children’s Hospital, Harvard, and Laval University, Axonis aims to enhance the lives of individuals affected by these disorders through improved modulation of neuronal inhibition.
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines targeting verified biology to improve care for patients with solid tumors.
Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.
Inhibikase Therapeutics has developed the first small molecule platform capable of treating both bacterial and viral infectious diseases through a common mechanism of action in the host. The company's host targeting strategy creates multi-pathogen anti-infectives without stimulating resistance.
OnKure Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative cancer therapies through the discovery of precision medicines that target biologically validated drivers of cancer. The company focuses on less toxic kinase inhibitor drugs, particularly selective inhibitors of histone deacetylases (HDACs). Its lead candidate, OKI-179, has demonstrated significant and safe tumor growth reduction in pre-clinical models for both hematological and solid tumors, either alone or in combination with other targeted therapies. Additionally, OnKure is advancing another candidate, OKI-422, into pre-clinical toxicology studies. The company's pipeline includes tumor-agnostic therapies that aim to enhance treatment efficacy and tolerability by directly targeting malignant cells and optimizing the tumor microenvironment for improved checkpoint inhibition.
Orpyx Medical Technologies Inc. specializes in developing mobility sensor devices aimed at diabetic patients. The company's flagship product, the Orpyx SI sensory insoles, employs advanced sensor technology to monitor pressure, temperature, and movement, thereby helping to manage and prevent diabetic foot ulcers and limb loss. Additionally, Orpyx offers Kinetyx, a mobile in-shoe pressure management system that captures clinical plantar pressure data for sports medicine and footwear design, along with SurroGait Rx, which aids multiple sclerosis patients in enhancing mobility and balance. Founded in 2010 and headquartered in Calgary, Canada, Orpyx Medical Technologies is committed to empowering individuals with diabetes to maintain their mobility while promoting a prevention-focused healthcare model.
scPharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic options for patients with serious medical conditions. The company’s lead product candidate, Furoscix, features a proprietary buffered formulation of furosemide delivered via the SmartDose drug delivery system, targeting congestion in patients with decompensated heart failure. In addition to Furoscix, scPharmaceuticals is advancing its product pipeline with scCeftriaxone, an antibiotic for infections from gram-positive and gram-negative organisms, and its scCarbapenem program, aimed at treating infections caused by gram-negative organisms. Founded in 2013 and headquartered in Burlington, Massachusetts, scPharmaceuticals aims to provide a convenient, safe, and effective alternative to intravenous drug administration through subcutaneous delivery, addressing the associated costs and risks. The company collaborates with West Pharmaceutical Services, Inc. to enhance the SmartDose system for Furoscix.
Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.
Private Equity Round in 2024
InSightec Ltd. specializes in developing and distributing the Exablate platform, which employs MR-guided focused ultrasound technology for non-invasive medical treatments in oncology and gynecology. The company offers solutions such as Exablate Neuro, designed for personalized thalamotomy to address movement disorders and pain without invasive surgery, and a thermal ablation technique for the treatment of uterine fibroids, which alleviates symptoms while minimizing damage to surrounding tissues. Founded in 1999 and headquartered in Tirat Carmel, Israel, InSightec has expanded its presence globally with operations in Europe, Asia, and the Americas. The Exablate system has received various regulatory approvals, including CE marks and FDA approval, and has been recognized with multiple innovation awards for its contributions to healthcare. In addition to its medical devices, InSightec provides clinical training, business support, maintenance, and customer services to healthcare facilities using its technology.
Talkiatry is a provider of virtual psychiatry services that connects patients with a team of over 300 licensed psychiatrists. The company focuses on making high-quality mental health care accessible and convenient, specializing in the treatment of conditions such as anxiety, depression, ADHD, and substance use disorders. Utilizing an interactive process with evidence-based assessments, Talkiatry offers preliminary diagnoses and severity evaluations, facilitating easier access to in-network healthcare. Through personalized treatment plans, including medication management when necessary, Talkiatry aims to improve the overall mental health treatment experience for patients.
Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycles, which are synthetic short peptides designed to stabilize their structural geometry through two loops. The company primarily targets oncology indications with significant unmet medical needs. Its lead product candidate, BT1718, is a Bicycle Toxin Conjugate currently undergoing Phase I/IIa clinical trials aimed at tumors expressing Membrane Type 1 matrix metalloprotease. Other oncology candidates include BT5528, also in Phase I/IIa trials targeting EphA2, and BT8009, which is in preclinical studies for Nectin-4. Additionally, Bicycle Therapeutics is developing THR-149, a plasma kallikrein inhibitor that has completed Phase I trials for diabetic macular edema. The company collaborates with various biopharmaceutical organizations to advance programs in areas like anti-infectives and cardiovascular health. Founded in 2009, Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. The company was founded in 2022 and is based in London, England.
CinDome Pharma is a Cincinnati-based pharmaceutical company focused on developing treatments for gastrointestinal diseases, particularly chronic gastroparesis, which affects millions of individuals. The company is engaged in the creation of innovative drug therapies, including a novel chemical entity known as CIN-102, which utilizes deuteration to enhance safety, effectiveness, and tolerability. Through its commitment to addressing the challenges posed by chronic gastroparesis, CinDome Pharma aims to improve the quality of life for patients suffering from this condition.
CereVasc, Inc. is a medical device company dedicated to developing innovative, minimally invasive treatments for neurological diseases. Founded in 2014 and based in Auburndale, Massachusetts, the company focuses on its flagship product, the eShunt System. This system provides an endovascularly deliverable cerebrospinal fluid shunt along with necessary delivery components, designed to eliminate the need for invasive surgical procedures, general anesthesia, and prolonged hospitalization associated with traditional treatments for communicating hydrocephalus. By offering a less invasive option, the eShunt System aims to enhance patient outcomes and reduce the overall costs of surgical interventions for this serious condition.
SOPHiA GENETICS is a healthcare technology company focused on advancing data-driven medicine and enhancing life sciences research. The company has developed the SOPHiA DDM™ Platform, a cloud-based software-as-a-service solution that analyzes complex multimodal data sets and various diagnostic modalities. This platform is utilized by over 780 hospitals, laboratories, and biopharma institutions worldwide. Headquartered in Switzerland, SOPHiA GENETICS also maintains a presence in France, the United States, and Brazil, underscoring its commitment to improving healthcare outcomes through innovative technology.
Adaptilens, LLC is focused on developing an injectable, physiologically adaptive intraocular lens that provides patients with clear vision at various distances without the need for eyeglasses or contact lenses. Incorporated in 2019 and based in Chestnut Hill, Massachusetts, the company's innovative lens mimics the function of the natural human lens, allowing the ciliary muscles within the eye to alter the shape of the lens. This unique design enables natural accommodation, enabling users to focus on both near and distant objects effectively. Adaptilens aims to enhance the quality of life for patients by offering a solution that facilitates excellent near, intermediate, and distance vision.
Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.
TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative antibody-based medicines aimed at improving outcomes for cancer patients. The company specializes in creating antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) to address oncologic diseases that exhibit significant unmet medical needs. TORL BioTherapeutics employs a strategic approach that includes target identification and early discovery work, allowing them to license promising drug programs and develop proprietary therapies with optimized characteristics. Through this pipeline, TORL BioTherapeutics is positioned to advance novel treatments that could significantly enhance patient care in oncology.
Zevra Therapeutics is a development-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for pain, ADHD, and other central nervous system diseases. The company is particularly focused on creating safer, abuse-resistant opioid pain relievers. Utilizing its proprietary Ligand Activated Therapy (LAT) platform, Zevra aims to enhance existing drugs and streamline the development process while safeguarding its intellectual property. Additionally, Zevra addresses the needs of patients with rare diseases by employing unique, data-driven strategies to overcome challenges in drug development. The company's mission centers on delivering transformative therapies to individuals facing limited or no treatment options, ultimately striving to improve the quality of life for those affected by these conditions.
Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.
Neurosterix is a biopharmaceutical company focused on developing innovative medicines for neurological disorders through a unique approach known as allosteric modulation. This method aims to address the limitations of traditional treatments, enhancing efficacy, safety, and tolerability for conditions such as schizophrenia and other neuropsychiatric disorders. By leveraging a specialized drug discovery and development platform, Neurosterix aspires to provide improved therapeutic options for underserved patient populations, ultimately aiming to enhance the quality of life for individuals affected by these challenging conditions.
Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.
Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). This chronic condition, which encompasses disorders such as ulcerative colitis and Crohn's disease, involves inflammation in the gastrointestinal tract. Spyre Therapeutics combines advanced antibody engineering with rational therapeutic combinations and precision medicine strategies to enhance patient selection. The company's goal is to create next-generation products that improve upon existing treatment options, which include anti-inflammatory drugs, immunosuppressants, and biologics. Through its robust pipeline, Spyre Therapeutics seeks to address the unmet needs of patients suffering from IBD.
Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.
Precision BioSciences, Inc. is a biotechnology company based in Durham, North Carolina, focused on genome editing and the development of therapeutic products. Utilizing its proprietary ARCUS genome editing platform, the company aims to create innovative solutions for human diseases and food applications. Precision BioSciences operates through two primary segments: Therapeutic and Food. The Therapeutic segment is engaged in developing allogeneic CAR T immunotherapies, with several candidates in clinical trials targeting various types of cancers, including acute lymphoblastic leukemia and multiple myeloma. Additionally, the company is involved in in vivo gene correction activities and has collaborations for developing treatments for chronic Hepatitis B. The Food segment concentrates on creating nutrition products. Founded in 2006, Precision BioSciences is dedicated to translating advanced gene editing technology into impactful products across the life sciences.
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the discovery and development of innovative therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist currently undergoing Phase I clinical trials for the treatment of acromegaly and neuroendocrine tumors. In addition to paltusotine, Crinetics is advancing other candidates, including CRN01941, an oral selective nonpeptide sst2 biased agonist for neuroendocrine tumors, an oral selective somatostatin type 5 receptor agonist for congenital hyperinsulinism, and an oral adrenocorticotropic hormone antagonist targeting Cushing’s disease and congenital adrenal hyperplasia. Founded in 2008 and headquartered in San Diego, California, Crinetics Pharmaceuticals aims to leverage its internal discovery efforts and objective hormonal biomarker endpoints to effectively navigate the development process and bring meaningful treatments to market.
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing innovative therapies for serious medical conditions with significant unmet needs. The company's lead product candidate, AT-007, is in phase I/II clinical trials for the treatment of galactosemia, while AT-001 is undergoing phase II trials for diabetic cardiomyopathy and phase I trials for diabetic peripheral neuropathy. Additionally, AT-003 is in phase I trials for diabetic retinopathy. The company also has preclinical candidates, such as AT-104, aimed at treating orphan hematological oncology conditions. Founded in 2016, Applied Therapeutics leverages advancements in technology and regulatory processes to create drugs targeting well-established molecular mechanisms.
Private Equity Round in 2024
Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.
Freenome, Inc. is a biotechnology company based in South San Francisco, California, founded in 2014. It specializes in developing artificial intelligence-driven genomic solutions for the early detection of cancer. The company focuses on creating simple, non-invasive blood tests that can identify early-stage cancer and assist in treatment selection, thus enabling proactive disease management. Freenome’s multi-omics platform employs proprietary algorithms to enhance disease screening processes, aiming to facilitate timely interventions and improve treatment effectiveness. In addition to its diagnostic products, Freenome also offers clinical research services to support its mission of transforming cancer management through systematic early detection.
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.
PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.
Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.
Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). This chronic condition, which encompasses disorders such as ulcerative colitis and Crohn's disease, involves inflammation in the gastrointestinal tract. Spyre Therapeutics combines advanced antibody engineering with rational therapeutic combinations and precision medicine strategies to enhance patient selection. The company's goal is to create next-generation products that improve upon existing treatment options, which include anti-inflammatory drugs, immunosuppressants, and biologics. Through its robust pipeline, Spyre Therapeutics seeks to address the unmet needs of patients suffering from IBD.
enVVeno Medical Corp is a medical device company dedicated to advancing the treatment of venous disease through the development of bioprosthetic devices. The company's flagship product, the VenoValve, represents a pioneering surgical implant designed to address severe deep venous Chronic Venous Insufficiency (CVI). By creating innovative tissue-based solutions, enVVeno Medical aims to enhance the standard of care for patients suffering from debilitating venous conditions. The company is committed to improving patient outcomes while streamlining surgical procedures for healthcare providers. Based in Irvine, California, enVVeno Medical continues to focus on developing technologies that promise to transform the management of venous diseases.
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare diseases. The company's primary focus is on its lead candidate, Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet designed for the treatment of Prader-Willi Syndrome (PWS). This product is currently undergoing evaluation in a Phase III clinical development program. Soleno Therapeutics was incorporated in 1999 and is based in Redwood City, California. The company was previously known as Capnia, Inc. before rebranding in May 2017.
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.
Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.
Inhibrx, Inc. is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing a diverse pipeline of novel biologic therapeutic candidates. The company employs advanced protein engineering techniques, including its proprietary sdAb platform, to target complex disease biology, with a focus on oncology, orphan diseases, and infectious diseases. Inhibrx's lead candidates include INBRX-109, a multivalent agonist in Phase 1 trials for solid tumors; INBRX-105, an antagonist of PD-L1 also in Phase 1 trials; INBRX-101, an Fc-fusion protein for alpha-1 antitrypsin deficiency; and INBRX-103, a monoclonal antibody targeting CD47. Additionally, the company is developing preclinical programs such as INBRX-106, an agonist of OX40, and INBRX-111, an antibody targeting Pseudomonas aeruginosa. Inhibrx has established collaborations with organizations like Celgene and Bluebird Bio and has received funding from various granting agencies, including the NIH and CARB-X.
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing innovative small-molecule therapies for neurological disorders. The company focuses on understanding the intricate biology of neuronal receptor complexes, which are essential for proper neuronal function and signaling. By mapping and targeting these receptor systems, Rapport Therapeutics aims to create precision medicines that can effectively address the unmet needs of patients suffering from central nervous system disorders. Through its foundational research, the company seeks to transform treatment options and improve outcomes for individuals with these challenging conditions.
Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company is developing innovative treatments for inflammatory skin diseases, with its lead product, FB-401, being a topically applied live biotherapeutic created in partnership with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte is advancing through preclinical trials for another product candidate, FB-102, which is a proprietary therapeutic molecule that may have applications in treating various autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata.
AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to design long-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body. AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases.
A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile.
OnKure Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative cancer therapies through the discovery of precision medicines that target biologically validated drivers of cancer. The company focuses on less toxic kinase inhibitor drugs, particularly selective inhibitors of histone deacetylases (HDACs). Its lead candidate, OKI-179, has demonstrated significant and safe tumor growth reduction in pre-clinical models for both hematological and solid tumors, either alone or in combination with other targeted therapies. Additionally, OnKure is advancing another candidate, OKI-422, into pre-clinical toxicology studies. The company's pipeline includes tumor-agnostic therapies that aim to enhance treatment efficacy and tolerability by directly targeting malignant cells and optimizing the tumor microenvironment for improved checkpoint inhibition.
Satellos Bioscience is a private regenerative medicine company dedicated to developing innovative therapeutics aimed at stimulating or restoring muscle regeneration, particularly in severe disorders. The company's primary focus is on creating an oral therapeutic drug for Duchenne muscular dystrophy, targeting the dysregulation that is recognized as a fundamental cause of the disease's progressive characteristics. Through its research and development efforts, Satellos aims to address significant unmet medical needs within the field of muscle-related conditions.
TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative antibody-based medicines aimed at improving outcomes for cancer patients. The company specializes in creating antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) to address oncologic diseases that exhibit significant unmet medical needs. TORL BioTherapeutics employs a strategic approach that includes target identification and early discovery work, allowing them to license promising drug programs and develop proprietary therapies with optimized characteristics. Through this pipeline, TORL BioTherapeutics is positioned to advance novel treatments that could significantly enhance patient care in oncology.
Kindbody is a fertility clinic network and family-building benefits provider that offers a comprehensive range of services aimed at supporting individuals and couples in their journey to parenthood. The company's offerings include fertility assessments, preservation, genetic testing, in vitro fertilization (IVF), as well as donor, surrogacy, and adoption services. Employers collaborate with Kindbody to provide their employees with essential financial, medical, and emotional support throughout the family-building process. Kindbody serves over 100 employers, impacting more than 2.4 million lives, while also delivering fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. The organization emphasizes improving access to holistic health and fertility services for women at affordable rates, utilizing modern technology to enhance the patient experience.
Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.
Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.
Anteris Technologies Ltd is a structural heart company based in Toowong, Australia, that focuses on the development and commercialization of innovative medical technologies and devices. The company is known for its DurAVR transcatheter heart valve, designed for younger patients requiring a durable heart valve that mimics the natural blood flow of a healthy aortic valve. Additionally, Anteris is engaged in the research and development of the ComASUR delivery system, which enhances the precision of valve placement. The company also manufactures and distributes proprietary ADAPT regenerative tissue products and is involved in regenerative medicine and immunotherapies. Anteris Technologies aims to provide clinically superior solutions that enable healthcare professionals to achieve life-changing outcomes for patients.
Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders. The company aims to advance novel therapies to address patients’ needs. Based in San Francisco, California, Apogee Therapeutics was founded in 2022.
Biodesix, Inc. is a diagnostic solutions company based in Boulder, Colorado, specializing in lung cancer diagnostics and biopharmaceutical services. The company offers a range of blood-based tests designed to assist physicians in evaluating the risk of malignancy in patients with suspicious lung nodules, including the Nodify XL2 and Nodify CDT tests. Additionally, it provides GeneStrat tumor profiling and VeriStrat immune profiling tests that enable more informed treatment decisions. Biodesix utilizes a proprietary mass spectrometry-based platform for the development of multivariate protein diagnostics, with its first product, VeriStrat, aiding oncologists in choosing between specific therapies for advanced lung cancer patients. The tests are processed in a CLIA-certified laboratory, with results delivered within 72 hours. Besides its diagnostic offerings, Biodesix collaborates with biopharmaceutical companies to develop companion diagnostics, enhancing the therapeutic effectiveness of various agents. Incorporated in 2005, Biodesix is committed to improving patient outcomes through innovative diagnostic solutions.
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA.
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients’ muscles. DMD is a progressive and ultimately fatal condition, with an estimated prevalence of 10,000 to 15,000 cases in the United States. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which targets the LTBP4 protein to reduce fibrosis and inflammation. The company also develops biomarkers, sensors, and the Solid Suit program, which includes wearable assistive devices designed to provide functional and therapeutic benefits. Established in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences collaborates with Ultragenyx to enhance its gene therapy initiatives for DMD.
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.
InSightec Ltd. specializes in developing and distributing the Exablate platform, which employs MR-guided focused ultrasound technology for non-invasive medical treatments in oncology and gynecology. The company offers solutions such as Exablate Neuro, designed for personalized thalamotomy to address movement disorders and pain without invasive surgery, and a thermal ablation technique for the treatment of uterine fibroids, which alleviates symptoms while minimizing damage to surrounding tissues. Founded in 1999 and headquartered in Tirat Carmel, Israel, InSightec has expanded its presence globally with operations in Europe, Asia, and the Americas. The Exablate system has received various regulatory approvals, including CE marks and FDA approval, and has been recognized with multiple innovation awards for its contributions to healthcare. In addition to its medical devices, InSightec provides clinical training, business support, maintenance, and customer services to healthcare facilities using its technology.
Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing implanted drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company utilizes a refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of its formulation of the anti-epileptic drug valproic acid, known as CT-010. This innovative approach aims to bypass the blood-brain barrier, enhancing treatment outcomes for patients with chronic neurological conditions. Founded in 2010, Cerebral Therapeutics is dedicated to improving the lives of individuals affected by uncontrolled neurological diseases.
Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas.
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile.
VivoSense, also known as Vivonoetics, is a data analysis and software company focused on providing wearable sensor physiological monitoring solutions for research and clinical trials. The company develops digital clinical measures designed to enhance patient research and care by delivering digital biomarkers derived from wearable sensor data. This platform allows researchers to collect and analyze real-world data accurately, facilitating informed decision-making and risk evaluation associated with various medical treatments in regulated clinical environments. Through its innovative approach, VivoSense aims to improve the efficiency and effectiveness of clinical research.
Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.
DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.
Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.
Synthego Corporation is a genome engineering company focused on advancing life science research and therapeutic development to improve human health. Founded in 2012 and headquartered in Redwood City, California, Synthego offers a comprehensive platform that integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology. The company's product portfolio includes engineered cells, CRISPR kits, and bioinformatics tools designed for various applications such as pathway analysis, target validation, disease modeling, and diagnostics. By leveraging machine learning and automation, Synthego enables researchers in biotechnology and academia to conduct efficient and precise gene editing, facilitating rapid advancements in drug discovery and development. The company serves a global customer base, distributing its products through various channels, including online sales and partnerships in multiple countries.
Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.
Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.
Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Its main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization. It was founded in 2017 and is headquartered in New Hope, Pennsylvania.
Ceptur Therapeutics is focused on developing innovative genetic medicines aimed at addressing diseases that currently lack effective treatments. The company utilizes its proprietary U1 Adaptor technology, which enables long-lasting and non-genotoxic silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and holds promise for cancer treatment, allowing healthcare providers to offer new therapeutic options for patients with various types of cancers.
AvengeBio is a biotechnology company based in Cambridge, Massachusetts, focused on developing cell-generated immunotherapies aimed at eradicating solid tumors. Founded in 2019, the company is advancing a drug delivery platform designed to enable the precision delivery of cytokines and other potent immunomodulatory molecules. This innovative approach allows for controlled release over time, fostering robust local and systemic anti-tumor immune responses while minimizing the toxicities typically associated with conventional immunotherapies. Through its research and development efforts, AvengeBio seeks to address the challenges posed by intractable solid tumors and improve treatment outcomes for cancer patients.
Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.
Mythic Therapeutics is a biotechnology company dedicated to advancing cancer treatment through innovative antibody-drug conjugates (ADCs). The company specializes in a protein engineering approach that enhances the potency of ADCs while maintaining safety, allowing for more effective targeted therapies across various tumor types. By improving the uptake of these therapeutics in cancerous cells and minimizing payload release in healthy cells, Mythic Therapeutics aims to increase the efficacy of treatments without causing significant side effects or toxicity. This technology positions the company to make a meaningful impact in cancer care, enabling healthcare practitioners to better utilize ADCs for a wide array of patients.
Sermonix Pharmaceuticals is a biotechnology company based in Columbus, Ohio, founded in 2014. The company specializes in the development and commercialization of female-specific oncology products, focusing on late-stage women’s health treatments. Its primary product, lasofoxifene, is a selective estrogen receptor modulator designed for the treatment of vulvovaginal atrophy and the treatment and prevention of post-menopausal osteoporosis. Additionally, Sermonix is involved in developing pharmaceutical drugs aimed at treating ESR1-mutated metastatic breast and gynecological cancers, thereby addressing critical needs in women's health and oncology.
Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Twin Health, Inc. is a precision health company focused on reversing diabetes and chronic diseases through its innovative health platform. Founded in 2018 and based in Mountain View, California, with additional offices in India, Twin Health utilizes artificial intelligence and Internet-of-Things technologies to accurately measure and address metabolic health issues, which are often the underlying causes of chronic conditions. The platform incorporates sensors and advanced machine learning to analyze biosignals from wearables, predict metabolic outcomes, and provide personalized treatment recommendations tailored to each patient's metabolic profile. The company has secured significant funding from prominent venture capital firms and holds multiple patents related to its technology, positioning it as a leader in the field of metabolic health.
Honor is the largest senior care network and technology platform globally, dedicated to enhancing the quality of life for older adults and their families. Founded in 2014 in San Francisco by Cameron Ring, Monica Lo, Sandy Jen, and Seth Sternberg, the company aims to improve in-home care services for seniors. In 2021, Honor expanded its reach by acquiring Home Instead, which strengthened its network and introduced a relationship-based care model. The company combines workforce management and technology expertise with personalized care delivered through a network of third-party providers. This integrated approach allows older adults to receive reliable, transparent, and quality care, enabling them to live safely and comfortably in their own homes.
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts.